31 Mar 2023
Assets133.96
Total Income97.03
EBITDA17.64
Profit After Tax4.38
NET Worth31.49
Reserves and Surplus24.34
Total Borrowing68.55
At a glance
Updated 2026-09-09Sai Parenteral's is a Mainboard IPO with an issue size of ₹408.79 crore, proposed for listing on BSE, NSE. The issue structure includes a fresh issue of ₹285.00 crore and an offer-for-sale component of ₹123.79 crore.
Issue details
Listing atBSE, NSE
Issue typeBook Build Issue
Issue size₹408.79 Cr
Fresh issue₹285.00 Cr
Offer for sale₹123.79 Cr
Face value₹5
Price band₹372.00–₹392.00
Grey market
GMP page ↗Latest GMPNO GMP
GMP / upper priceNO DATA
Est. listingNO DATA
GMP is unofficial sentiment data, not an exchange price.
Subscription demand
Full bidding ↗QIB1.73×
sHNI0.24×
bHNI3.56×
NII / HNI3.56×
Retail0.12×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,896 |
| Retail (Max) | 13 | 494 | ₹193,648 |
| S-HNI (Min) | 14 | 532 | ₹208,544 |
| S-HNI (Max) | 67 | 2546 | ₹998,032 |
| B-HNI (Min) | 68 | 2584 | ₹1,012,928 |
Reservation
Issue mix
sNII < ₹10L5.00%521,414 shares
Retail35.00%3,649,901 shares
Total100.00%10,428,288 shares
Company
Use of proceeds
| Object | Amount |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | ₹110.80 Cr |
| Establishment of a new R&D Centre; | ₹18.02 Cr |
| Repayment / prepayment of certain outstanding borrowings | ₹14.30 Cr |
| Working capital requirements | ₹33.00 Cr |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | ₹35.64 Cr |
| General corporate purposes | ₹44.74 Cr |
| Issue Expenses | ₹40.84 Cr |
| Total | ₹297.34 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue89.43₹ Cr · -45.4% vs prior year
EBITDA16.24₹ Cr · -58.8% vs prior year
PAT7.76₹ Cr · -46.2% vs prior year
Assets376.24₹ Cr · +38.1% vs prior year
Net Worth209.37₹ Cr · +118.6% vs prior year
Borrowing76.07₹ Cr · -19.0% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2024
Assets268.10
Total Income155.18
EBITDA31.70
Profit After Tax8.42
NET Worth76.40
Reserves and Surplus61.30
Total Borrowing118.79
31 Mar 2025
Assets272.39
Total Income163.74
EBITDA39.44
Profit After Tax14.43
NET Worth95.78
Reserves and Surplus80.36
Total Borrowing93.95
30 Sep 2025
Assets376.24
Total Income89.43
EBITDA16.24
Profit After Tax7.76
NET Worth209.37
Reserves and Surplus188.84
Total Borrowing76.07
KPIs
| KPI | Mar 31, 2025 | Sep 30, 2025 |
|---|---|---|
| ROE | 16.82% | 5.13% |
| ROCE | 28.92% | 9.28% |
| RoNW | 15.09% | 5.09% |
| PAT Margin | 8.88% | 8.93% |
| EBITDA Margin | 24.18% | 18.68% |
| Price to Book Value | 10.89 |
Valuation & shareholding
Pre-IPO EPS5.43
Pre-IPO P/E72.19
Promoter holding pre61.23%
Promoter holding post51.16%
Market cap₹1731.83 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Sai Parenteral's IPO | — | 111.58 x | — | — |
| Symbiotec Pharmalab IPO | — | 61.88 x | — | — |
| Corona Remedies IPO | — | 35.15 x | — | — |
| Sudeep Pharma IPO | — | 53.55 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | ₹110.80 Cr |
| Establishment of a new R&D Centre; | ₹18.02 Cr |
| Repayment / prepayment of certain outstanding borrowings | ₹14.30 Cr |
| Working capital requirements | ₹33.00 Cr |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | ₹35.64 Cr |
| General corporate purposes | ₹44.74 Cr |
| Issue Expenses | ₹40.84 Cr |
| Total | ₹297.34 Cr |
Registrar & lead managers
Registrar
Bigshare Services Pvt.Ltd.Lead managers
- Arihant Capital Markets Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-09.
IPO UPDATE ALERTS
Register for IPO Updates →Track Sai Parenteral’s without missing an update
Register for subscription, GMP, allotment and listing notifications.